Linda Yaccarino, the former X CEO who left the social media company last month in the wake of yet another Elon Musk controversy, has been named the top executive at health company eMed.

eMed Population Health provides support for patients on GLP-1 medications, such as Wegovy and Ozempic, that treat diabetes and obesity.

“Our mission is revolutionizing how people receive safe, effective care for chronic condition management through GLP-1 therapies, while building the programs and technologies needed to sustain lasting health outcomes,” Yaccarino wrote in a post on Tuesday announcing her new role as CEO.

“This is truly a transformational moment in preventative healthcare, and I’m energized by the opportunity to help lead what could become the most impactful health initiative of our time,” she added.

In a statement, eMed said Yaccarino’s experience would be “instrumental” as the company looks to expand its services to accommodate more “national and global employer and government partnerships.”

Yaccarino left X in July after two years as CEO, a day after the company’s AI chatbot Grok declared itself “MechaHitler” and repeatedly sexually harassed Yaccarino. It’s unclear if her exit was directly connected to Grok’s outbursts but the company later apologized, blaming a system update.

Her time with X was filled up upheaval as Musk caused one controversy after another, leading to an exodus of advertisers.

Yaccarino previously served as NBCUniversal Media’s chair of global advertising and partnerships.

eMed was launched in 2020, offering COVID-19 tests and services before pivoting to weight-loss drugs.

©2025 New York Daily News. Visit at nydailynews.com. Distributed by Tribune Content Agency, LLC.